Safety, Tolerability, Pharmacokinetics, and the Effect of Food on TERN-701, an Oral Allosteric BCR-ABL Tyrosine Kinase Inhibitor, in Healthy Participants

被引：0
|
作者：
Anderson, Kacey [1 ]
Holes, Leanne [1 ]
Marmon, Tonya [1 ]
Nichols, Andie [1 ]
Schlegel, Amnon [1 ]
Nelson, Cara [1 ]
Kuriakose, Emil [1 ]
机构：
[1] Terns Pharmaceut, Foster City, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
CML; TERN-701; allosteric BCR-ABL1 tyrosine kinase inhibitor; phase; 1; safety;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-396
引用
收藏
页码：S370 / S370
页数：1
相关论文
共 50 条
  • [31] FIRST-IN-HUMAN STUDY OF GS-5718, AN ORAL IRAK-4 INHIBITOR, IN HEALTHY SUBJECTS: PHARMACOKINETICS, SAFETY, TOLERABILITY, AND ASSESSMENT OF EFFECT OF FOOD AND ACID REDUCING AGENTS ON EXPOSURE
    Anderson, K.
    Hsueh, C. H.
    Gurtovaya, O.
    Mathur, A.
    Taylor, J.
    Serone, A.
    Othman, A. A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 581 - 581
  • [32] Inhibitory Effect of Ketoconazole on the Pharmacokinetics of a Multireceptor Tyrosine Kinase Inhibitor BMS-690514 in Healthy Participants: Assessing the Mechanism of the Interaction With Physiologically-Based Pharmacokinetic Simulations
    Yang, Zheng
    Vakkalagadda, Blisse
    Shen, Guoxiang
    Ahlers, Christoph M.
    Has, Teresa
    Christopher, Lisa J.
    Kurland, John F.
    Roongta, Vikram
    Masson, Eric
    Zhang, Steven
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (02): : 217 - 227
  • [33] Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants
    Catlett, Ian M.
    Nowak, Miroslawa
    Kundu, Sudeep
    Zheng, Naiyu
    Liu, Ang
    He, Bing
    Girgis, Ihab G.
    Grasela, Dennis M.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 86 (09) : 1849 - 1859
  • [34] An Updated Safety and Efficacy Results of Phase 1 Study of HQP1351, a Novel 3rd Generation of BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI Resistant Chronic Myeloid Leukemia
    Jiang, Qian
    Huang, Xiaojun
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Ji, Jiao
    Huang, Bo
    Shi, Dayu
    Zhao, Ting
    Hou, Yue
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2019, 134
  • [35] Preliminary activity of AMN107, a novel potent oral selective Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP).
    Jabbour, E.
    Giles, F.
    Cortes, J.
    O'Brien, S.
    Ravandi, F.
    Borthakur, G.
    Garcia-Manero, G.
    Letvak, L.
    Salvado, A.
    Kantarjian, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 358S - 358S
  • [36] Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
    Qian, Jiang
    Shi, Dayu
    Li, Zongru
    Qin, Yazhen
    Zhao, Ting
    Liu, Bingcheng
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Huan, Xiaojun
    BLOOD, 2021, 138
  • [37] Single-and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects
    Eckburg, Paul B.
    Ge, Yigong
    Hafkin, Barry
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (04)
  • [38] A randomized, placebo-controlled first-in-human study of oral TQS-168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect
    Hannestad, Jonas
    Smith, Steven
    Lam, Andrew
    Hurt, Janet
    Harada, Nicole
    Kim, Richard
    Das, Abhirup
    Brunello, Juliana
    Whitaker, Gareth
    Chalmers, David
    Senjoti, Faria
    Lin, Wu
    Coghill, James
    Bansal, Yogesh
    Sidhu, Sharan
    Zann, Vanessa
    Liu, Enchi
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (11):
  • [39] Cyclosporine has no clinically meaningful effect on pharmacokinetics (PK) of BMS-986165, an oral selective tyrosine kinase 2 (TYK2) inhibitor, in healthy subjects
    Chimalakonda, A.
    Jones, J., III
    Dockens, R.
    Throup, J.
    Banerjee, S.
    Girgis, I.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S277 - S278
  • [40] Preliminary activity of nilotinib (AMN107), a novel selective potent oral Bcr-Abl tyrosine kinase inhibitor, in newly diagnosed Philadelphia chromosome (Ph)-positive chronic phase chronic myelogenous leukemia (CML-CP).
    Jabbour, Elias
    Cortes, Jorge
    Giles, Francis
    O'Brien, Susan
    Letvak, Laurie
    Kantarjian, Hagop
    BLOOD, 2006, 108 (11) : 616A - 616A
12345